Daniele Santini

Pubblicazioni

Titolo Pubblicato in Anno
Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7) JOURNAL OF CLINICAL ONCOLOGY 2020
Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study JOURNAL OF CLINICAL ONCOLOGY 2020
Role of glyoxalase-1 in trabectedin-resistant myxoid liposarcoma JOURNAL OF CLINICAL ONCOLOGY 2020
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy FRONTIERS IN ONCOLOGY 2020
Coronavirus disease 2019 or lung cancer: what should we treat? JOURNAL OF THORACIC ONCOLOGY 2020
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2020
Bone health in cancer: ESMO Clinical Practice Guidelines ANNALS OF ONCOLOGY 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy JOURNAL OF CLINICAL MEDICINE 2020
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis CLINICAL COLORECTAL CANCER 2020
Facing SARS-CoV-2 outbreak in immunotherapy era FUTURE ONCOLOGY 2020
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? CLINICAL MEDICINE INSIGHTS: ONCOLOGY 2020
Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study JOURNAL OF CLINICAL ONCOLOGY 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak era ESMO OPEN 2020
Response to cabozantinib in renal cell carcinoma with cardiac metastases ANTI-CANCER DRUGS 2020
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion ESMO OPEN 2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest EUROPEAN JOURNAL OF CANCER 2020
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol BMJ OPEN 2020
Denosumab for cancer-related bone loss EXPERT OPINION ON BIOLOGICAL THERAPY 2020
Recent advances in desmoid tumor therapy CANCERS 2020
Steroid-refractory immune related hepatitis may hide viral re-activation FUTURE SCIENCE OA 2020

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma